Goldman Sachs asks in biotech Report: Is curing patients a sustainable business? (2018)

> "Is curing patients a sustainable business?"

The question is: If a capitalist (or agent in a capitalist system) has a choice between a) investing to produce/producing a cure, or b) investing to produce/producing a more-or-less working symptomatic relief, how many agents/capitalists (in decision-making positions) go for choice B, which essentially turns them into legal drug pushers with a money-printing license?

Capitalist system solve this with competition. If there is already market of people paying for more-or-less working symptomatic relief then it's proof these people are actually a good market to sell a cure for x100 price of relief.